Loomis Sayles & Co. L P Trims Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Loomis Sayles & Co. L P lowered its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 31.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 417,208 shares of the biopharmaceutical company’s stock after selling 195,158 shares during the quarter. Loomis Sayles & Co. L P owned about 0.73% of Agios Pharmaceuticals worth $13,709,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Quest Partners LLC increased its stake in Agios Pharmaceuticals by 139.6% in the 3rd quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 1,283 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of Agios Pharmaceuticals in the third quarter worth approximately $892,000. Charles Schwab Investment Management Inc. raised its stake in Agios Pharmaceuticals by 1.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 465,620 shares of the biopharmaceutical company’s stock valued at $20,687,000 after purchasing an additional 8,093 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Agios Pharmaceuticals by 4.1% during the third quarter. The Manufacturers Life Insurance Company now owns 143,431 shares of the biopharmaceutical company’s stock valued at $6,373,000 after purchasing an additional 5,587 shares during the last quarter. Finally, FMR LLC grew its stake in Agios Pharmaceuticals by 283.2% in the 3rd quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company’s stock worth $2,017,000 after buying an additional 33,546 shares in the last quarter.

Agios Pharmaceuticals Price Performance

Shares of AGIO stock opened at $30.28 on Friday. The business has a 50-day moving average of $33.17 and a 200 day moving average of $40.87. The stock has a market capitalization of $1.73 billion, a PE ratio of 2.67 and a beta of 0.90. Agios Pharmaceuticals, Inc. has a 1-year low of $27.14 and a 1-year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Analyst Upgrades and Downgrades

AGIO has been the topic of several research reports. StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. HC Wainwright assumed coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They set a “buy” rating and a $58.00 price objective on the stock. Scotiabank raised their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, December 9th. Finally, Royal Bank of Canada upped their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Agios Pharmaceuticals has an average rating of “Hold” and a consensus target price of $56.57.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the transaction, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.93% of the stock is currently owned by company insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.